Europos Sąjunga - islandų - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - Önnur háþiýstingslækkandi - meðferð á lungnaslagæðaháþrýstingi (pah) til að bæta æfingargetu og einkenni hjá sjúklingum með who-virkni í flokki iii. verkun hefur verið sýnt fram á:aðal (sjálfvakin og ættingja) pah;pah efri að liðagigt án verulega millibils lungnasjúkdóm;pah tengslum með meðfædda almenn-til-í lungum shunts og eisenmenger er lífeðlisfræði. nokkrar endurbætur hafa líka verið sýnt fram í sjúklinga með pah sem hagnýtur ii. stayveer er einnig ætlað að fækka nýja stafræna sár í sjúklinga með almenna mænusigg og áframhaldandi stafræna-magasár.

Europos Sąjunga - islandų - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , þrefaldur samsetning meðferð) sem viðbót til að fæði og æfing í sjúklingar ekki nægilega stjórn á eigin hámarks þolað skammt af sjúklingar og sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europos Sąjunga - islandų - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 30 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 50 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 70 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 20 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 40 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 60 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - citalopram hydrobromide - filmuhúðuð tafla - 20 mg